SIDT1

Summary

SIDT1 (SID1 transmembrane family member 1, HGNC:25967) is a protein-coding gene on chromosome 3q13.2, encoding SID1 transmembrane family member 1 (Q9NXL6). In vitro binds long double-stranded RNA (dsRNA) (500 and 700 base pairs), but not dsRNA shorter than 300 bp.

The protein encoded by this gene belongs to SID1 family of transmembrane dsRNA-gated channels. Family members transport dsRNA into cells and are required for systemic RNA interference.

Source: NCBI Gene 54847 — RefSeq curated summary.

At a glance

• GWAS associations: 6
• Clinical variants (ClinVar): 136 total
• MANE Select transcript: NM_017699

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:25967
Approved symbol	SIDT1
Name	SID1 transmembrane family member 1
Location	3q13.2
Locus type	gene with protein product
Status	Approved
Aliases	FLJ20174, SID-1
Ensembl gene	ENSG00000072858
Ensembl biotype	protein_coding
OMIM	606816
Entrez	54847

Gene structure

Transcript identifiers

Ensembl transcripts: 22 — 12 protein_coding, 9 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000264852, ENST00000393830, ENST00000463226, ENST00000465803, ENST00000468728, ENST00000480746, ENST00000481891, ENST00000483946, ENST00000488390, ENST00000491730, ENST00000492863, ENST00000498152, ENST00000876685, ENST00000876686, ENST00000876687, ENST00000876689, ENST00000876691, ENST00000876692, ENST00000876693, ENST00000876694, ENST00000876695, ENST00000950250

RefSeq mRNA: 9 — MANE Select: NM_017699 NM_001308350, NM_001322294, NM_001322295, NM_001322296, NM_001322297, NM_001322298, NM_001322299, NM_001322300, NM_017699

CCDS: CCDS2974, CCDS77790

Canonical transcript exons

ENST00000264852 — 25 exons

Exon	Start	End
ENSE00000775478	113581361	113581444
ENSE00000775479	113583409	113583496
ENSE00000775480	113584698	113584769
ENSE00000823539	113616100	113616176
ENSE00001642093	113607041	113607114
ENSE00001852811	113627646	113629575
ENSE00001862415	113532555	113533243
ENSE00003464252	113623623	113623733
ENSE00003465033	113619680	113619726
ENSE00003501182	113567540	113567710
ENSE00003501258	113608419	113608536
ENSE00003502094	113566420	113566541
ENSE00003514364	113593005	113593048
ENSE00003519735	113626102	113626215
ENSE00003538436	113608094	113608217
ENSE00003570233	113580608	113580709
ENSE00003580797	113623427	113623532
ENSE00003581777	113601588	113601659
ENSE00003619963	113612086	113612194
ENSE00003621539	113603960	113604033
ENSE00003636693	113604910	113604976
ENSE00003650257	113611008	113611144
ENSE00003668443	113576922	113576967
ENSE00003675701	113585177	113585270
ENSE00003691310	113603005	113603150

Expression profiles

Bgee: expression breadth ubiquitous, 234 present calls, max score 87.83.

FANTOM5 (CAGE): breadth broad, TPM avg 5.7473 / max 147.9307, expressed in 489 samples.

FANTOM5 promoters (7 alternative TSS)

Promoter ID	TPM avg	Samples expressed
37963	3.8806	413
37964	0.8849	295
37968	0.3416	69
37965	0.2012	141
37966	0.1743	97
37962	0.1449	102
37967	0.1199	45

Top tissues by expression

281 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right hemisphere of cerebellum	UBERON:0014890	87.83	gold quality
cerebellar hemisphere	UBERON:0002245	87.70	gold quality
cerebellar cortex	UBERON:0002129	87.68	gold quality
rectum	UBERON:0001052	87.07	gold quality
cerebellum	UBERON:0002037	86.81	gold quality
mucosa of sigmoid colon	UBERON:0004993	85.91	gold quality
granulocyte	CL:0000094	84.92	gold quality
right frontal lobe	UBERON:0002810	83.95	gold quality
colonic mucosa	UBERON:0000317	83.92	gold quality
tonsil	UBERON:0002372	83.68	gold quality
lymph node	UBERON:0000029	81.92	gold quality
spleen	UBERON:0002106	81.59	gold quality
gall bladder	UBERON:0002110	81.11	gold quality
dorsolateral prefrontal cortex	UBERON:0009834	80.91	gold quality
Brodmann (1909) area 9	UBERON:0013540	80.57	gold quality
frontal cortex	UBERON:0001870	80.26	gold quality
bronchial epithelial cell	CL:0002328	80.23	gold quality
prefrontal cortex	UBERON:0000451	79.74	gold quality
blood	UBERON:0000178	79.52	gold quality
anterior cingulate cortex	UBERON:0009835	79.43	gold quality
neocortex	UBERON:0001950	79.32	gold quality
small intestine Peyer’s patch	UBERON:0003454	79.32	gold quality
cingulate cortex	UBERON:0003027	79.31	gold quality
bone marrow cell	CL:0002092	78.31	gold quality
leukocyte	CL:0000738	78.15	gold quality
superior frontal gyrus	UBERON:0002661	78.15	gold quality
male germ line stem cell (sensu Vertebrata) in testis	CL:0000089 ∩ UBERON:0000473	78.13	gold quality
cerebellar vermis	UBERON:0004720	78.03	silver quality
cerebral cortex	UBERON:0000956	78.01	gold quality
pituitary gland	UBERON:0000007	77.90	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	10.81
E-MTAB-6386	no	371.66

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): STAT6

miRNA regulators (miRDB)

106 targeting SIDT1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4673	100.00	66.64	1490
HSA-MIR-4425	100.00	67.59	1049
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-29A-3P	100.00	73.11	1835
HSA-MIR-29B-3P	100.00	73.18	1833
HSA-MIR-29C-3P	100.00	73.15	1833
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-186-5P	99.99	70.83	3707
HSA-MIR-34A-5P	99.99	71.21	1784
HSA-MIR-449A	99.99	71.05	1776
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-4645-5P	99.98	65.81	1284
HSA-MIR-4775	99.98	75.00	6394
HSA-MIR-34C-5P	99.97	70.45	1577
HSA-MIR-449B-5P	99.97	70.26	1580
HSA-MIR-6778-3P	99.96	67.29	2693
HSA-MIR-6721-5P	99.93	68.92	2981
HSA-MIR-497-5P	99.92	71.83	2674
HSA-MIR-6809-3P	99.91	71.45	3814
HSA-MIR-15A-5P	99.90	72.80	2787
HSA-MIR-15B-5P	99.90	72.78	2798
HSA-MIR-16-5P	99.90	72.80	2780
HSA-MIR-195-5P	99.90	72.81	2805
HSA-MIR-424-5P	99.89	71.90	2641
HSA-MIR-6838-5P	99.89	71.94	2690
HSA-MIR-6780A-5P	99.88	66.69	2776
HSA-MIR-3065-3P	99.87	70.25	1407
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-205-5P	99.81	70.05	1557

Literature-anchored findings (GeneRIF, showing 7)

• SIDT1, facilitates rapid, contact-dependent, bidirectional small RNA transfer between human cells, resulting in target-specific non-cell-autonomous RNAi (PMID:22174421)
• characterization of Sid-1 extracellular domain (PMID:22509261)
• In silico analysis identified SIDT1 and SIDT2 sharing identity and conserved cholesterol binding (CRAC) domains with C. elegans ChUP-1. Further evidence indicate that SIDT1 and SIDT2 not only do not transport RNA, but they are involved in cholesterol transport. Single point mutations in the CRAC domains of both proteins prevent FRET between SIDT1, SIDT2 and dehydroergosterol and alter cholesterol transport. (PMID:28785058)
• Human SIDT1 mediates dsRNA uptake via its phospholipase activity. (PMID:37932444)
• Characterization of N-glycosylation and its functional role in SIDT1-Mediated RNA uptake. (PMID:38237680)
• Cryo-EM analysis reveals human SID-1 transmembrane family member 1 dynamics underlying lipid hydrolytic activity. (PMID:38811802)
• Structure of the human systemic RNAi defective transmembrane protein 1 (hSIDT1) reveals the conformational flexibility of its lipid binding domain. (PMID:38925866)

Cross-species orthologs

3 orthologs

Organism	Symbol	Gene ID
mus_musculus	Sidt1	ENSMUSG00000022696
rattus_norvegicus	Sidt1	ENSRNOG00000002013
caenorhabditis_elegans		WBGENE00006477

Paralogs (1): SIDT2 (ENSG00000149577)

Protein

Protein identifiers

SID1 transmembrane family member 1 — Q9NXL6 (reviewed: Q9NXL6)

All UniProt accessions (1): Q9NXL6

UniProt curated annotations — full annotation on UniProt →

Function. In vitro binds long double-stranded RNA (dsRNA) (500 and 700 base pairs), but not dsRNA shorter than 300 bp. Not involved in RNA autophagy, a process in which RNA is directly imported into lysosomes in an ATP-dependent manner, and degraded.

Subcellular location. Membrane.

Similarity. Belongs to the SID1 family.

Isoforms (2)

UniProt ID	Names	Canonical?
Q9NXL6-1	1	yes
Q9NXL6-2	2

RefSeq proteins (9): NP_001295279, NP_001309223, NP_001309224, NP_001309225, NP_001309226, NP_001309227, NP_001309228, NP_001309229, NP_060169* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR025958	SID1_TM_fam	Family

Pfam: PF13965

UniProt features (103 total): strand 29, helix 22, topological domain 12, transmembrane region 11, turn 10, glycosylation site 8, compositionally biased region 3, sequence variant 3, signal peptide 1, chain 1, region of interest 1, splice variant 1, sequence conflict 1

Structure

Experimental structures (PDB)

14 structures.

PDB	Method	Resolution (Å)
8JUN	ELECTRON MICROSCOPY	2.38
8WOR	ELECTRON MICROSCOPY	2.66
8J6M	ELECTRON MICROSCOPY	2.77
8KCW	ELECTRON MICROSCOPY	2.77
8WOQ	ELECTRON MICROSCOPY	2.85
8JUL	ELECTRON MICROSCOPY	2.92
8KCX	ELECTRON MICROSCOPY	2.96
8WOT	ELECTRON MICROSCOPY	3.18
8K13	ELECTRON MICROSCOPY	3.33
8WOS	ELECTRON MICROSCOPY	3.37
8K1B	ELECTRON MICROSCOPY	3.47
8V38	ELECTRON MICROSCOPY	3.5
8K1D	ELECTRON MICROSCOPY	3.53
9M8U	ELECTRON MICROSCOPY	3.79

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q9NXL6-F1	80.90	0.51

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Glycosylation sites (8): 57, 67, 83, 136, 282, 471, 567, 764

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 0 (showing top):

GO Biological Process (1): RNA transport (GO:0050658)

GO Molecular Function (4): double-stranded RNA binding (GO:0003725), cholesterol binding (GO:0015485), RNA transmembrane transporter activity (GO:0051033), RNA binding (GO:0003723)

GO Cellular Component (3): lysosome (GO:0005764), plasma membrane (GO:0005886), membrane (GO:0016020)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
nucleic acid transport	1
establishment of RNA localization	1
RNA binding	1
sterol binding	1
alcohol binding	1
RNA transport	1
nucleic acid transmembrane transporter activity	1
nucleic acid binding	1
lytic vacuole	1
membrane	1
cell periphery	1
cellular anatomical structure	1

Protein interactions and networks

STRING

1644 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
SIDT1	UNC119	Q13432	780
SIDT1	DICER1	Q9UPY3	706
SIDT1	IGDCC3	Q8IVU1	694
SIDT1	CDC14A	Q9UNH5	674
SIDT1	ERI1	Q8IV48	631
SIDT1	LATS1	O95835	522
SIDT1	MORF4L1	Q9UBU8	485
SIDT1	AGO1	Q9UL18	476
SIDT1	ZC3H12D	A2A288	475
SIDT1	PIWIL1	Q96J94	461
SIDT1	PIWIL4	Q7Z3Z4	461
SIDT1	MOB1A	Q9H8S9	460
SIDT1	AGO2	Q9UKV8	452
SIDT1	PGAP6	Q9HCN3	448
SIDT1	EBAG9	O00559	447

IntAct

3 interactions, top by confidence:

A	B	Type	Score
NEK4	E2F8	psi-mi:“MI:0914”(association)	0.350
SIDT1	proA	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (5): SIDT1 (Affinity Capture-MS), SIDT1 (Affinity Capture-MS), SIDT1 (Affinity Capture-MS), SIDT1 (Protein-RNA), TRAP1 (Cross-Linking-MS (XL-MS))

ESM2 similar proteins: A0A1B0GST9, A0A1B0GTU2, A0A1B0GV90, A0A590UK83, A2RRL7, A7S641, A8WG88, A9JTJ0, B9X187, K7EJ46, O00168, O08589, O13001, P0C2S0, P15383, P41237, P56513, P60606, P63160, P63161, Q04645, Q04646, Q04679, Q04680, Q0P467, Q28EH9, Q3SZX0, Q3UJ81, Q3URE8, Q3ZBP2, Q4LDR2, Q4R6L9, Q502I1, Q592E4, Q5XF36, Q6AXF6, Q6NWH5, Q6PBK8, Q6Q3F5, Q71RC9

Diamond homologs: D3ZEH5, Q6AXF6, Q6Q3F5, Q8CIF6, Q8NBJ9, Q9GYF0, Q9NXL6, Q9GZC8

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

136 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	116
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

3849 predictions. Top by Δscore:

Variant	Effect	Δscore
3:113566416:GCA:G	acceptor_loss	1.0000
3:113566417:CAG:C	acceptor_loss	1.0000
3:113566418:A:AT	acceptor_loss	1.0000
3:113566537:GGACT:G	donor_gain	1.0000
3:113566538:GACT:G	donor_gain	1.0000
3:113566538:GACTG:G	donor_gain	1.0000
3:113566542:G:GG	donor_gain	1.0000
3:113566546:G:GG	donor_gain	1.0000
3:113567524:A:AG	acceptor_gain	1.0000
3:113567524:ATATT:A	acceptor_gain	1.0000
3:113567525:T:G	acceptor_gain	1.0000
3:113567526:A:AG	acceptor_gain	1.0000
3:113567526:ATT:A	acceptor_gain	1.0000
3:113567526:ATTG:A	acceptor_gain	1.0000
3:113567527:T:G	acceptor_gain	1.0000
3:113567528:T:A	acceptor_gain	1.0000
3:113567529:G:A	acceptor_gain	1.0000
3:113567535:TTCA:T	acceptor_loss	1.0000
3:113567538:A:AG	acceptor_gain	1.0000
3:113567539:G:GA	acceptor_gain	1.0000
3:113567539:GA:G	acceptor_gain	1.0000
3:113567539:GAT:G	acceptor_gain	1.0000
3:113567708:CCGG:C	donor_loss	1.0000
3:113567710:GGTAA:G	donor_loss	1.0000
3:113567711:G:GA	donor_loss	1.0000
3:113567711:G:GG	donor_gain	1.0000
3:113567712:T:G	donor_loss	1.0000
3:113580607:GT:G	acceptor_gain	1.0000
3:113581341:A:AG	acceptor_gain	1.0000
3:113581348:A:AG	acceptor_gain	1.0000

AlphaMissense

5480 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
3:113604957:T:C	L462P	1.000
3:113608509:T:C	C565R	1.000
3:113608510:G:A	C565Y	1.000
3:113608511:C:G	C565W	1.000
3:113604945:C:A	P458H	0.999
3:113604945:C:G	P458R	0.999
3:113607071:T:A	C479S	0.999
3:113607071:T:C	C479R	0.999
3:113607072:G:A	C479Y	0.999
3:113607072:G:C	C479S	0.999
3:113607073:T:G	C479W	0.999
3:113607089:T:A	C485S	0.999
3:113607089:T:C	C485R	0.999
3:113607090:G:C	C485S	0.999
3:113608491:A:C	S559R	0.999
3:113608493:T:A	S559R	0.999
3:113608493:T:G	S559R	0.999
3:113608509:T:A	C565S	0.999
3:113608510:G:C	C565S	0.999
3:113608513:C:A	P566H	0.999
3:113608526:C:A	N570K	0.999
3:113608526:C:G	N570K	0.999
3:113608533:T:C	F573L	0.999
3:113608534:T:G	F573C	0.999
3:113608535:C:A	F573L	0.999
3:113608535:C:G	F573L	0.999
3:113611008:A:T	D574V	0.999
3:113611064:C:A	R593S	0.999
3:113611067:C:G	H594D	0.999
3:113611113:C:A	A609D	0.999

dbSNP variants (sampled 300 via entrez): RS1000000030 (3:113534208 A>T), RS1000034132 (3:113633124 A>G,T), RS1000052448 (3:113607865 G>A), RS1000065940 (3:113535666 A>T), RS1000111601 (3:113614011 C>G,T), RS1000232070 (3:113621046 T>C), RS1000240618 (3:113568503 A>C), RS1000243437 (3:113544379 C>T), RS1000248869 (3:113620420 T>C), RS1000265937 (3:113578283 G>A), RS1000318818 (3:113541523 C>A,T), RS1000320082 (3:113562479 A>G), RS1000339519 (3:113566668 G>A,C), RS1000381381 (3:113602027 G>C), RS1000409024 (3:113557332 C>T)

Disease associations

OMIM: gene MIM:606816 | disease phenotypes:

GenCC curated gene-disease

Mondo (1): long QT syndrome (MONDO:0002442)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

6 associations (top):

Study	Trait	p-value
GCST001786_13	Dental caries	2.000000e-06
GCST001942_7	Prostate cancer	4.000000e-13
GCST004599_78	Mean platelet volume	3.000000e-10
GCST009597_158	Multiple sclerosis	7.000000e-07
GCST011320_4	Type 2 diabetes or prostate cancer (pleiotropy)	2.000000e-12
GCST90002395_379	Mean platelet volume	5.000000e-19

MeSH disease descriptors (1)

Descriptor	Name	Tree numbers
D008133	Long QT Syndrome	C14.280.067.565; C14.280.123.625; C16.131.240.400.715; C23.550.073.547

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

18 total (human), top 18 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Copper	affects cotreatment, decreases expression, affects binding	2
Nickel	increases expression	2
Aflatoxin B1	decreases methylation, increases methylation	2
triphenyl phosphate	affects expression	1
sodium arsenite	affects splicing, decreases expression	1
benzo(e)pyrene	decreases methylation	1
glycidamide	decreases expression	1
CGP 52608	affects binding, increases reaction	1
abrine	decreases expression	1
NSC 689534	affects binding, decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Air Pollutants, Occupational	affects expression	1
Benzo(a)pyrene	increases methylation	1
Cisplatin	increases expression	1
Estradiol	affects cotreatment, decreases expression	1
Methapyrilene	decreases methylation	1
Silicon Dioxide	decreases expression	1
Tobacco Smoke Pollution	decreases expression	1

Cellosaurus cell lines

3 cell lines: 2 cancer cell line, 1 transformed cell line

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_B1HJ	Abcam A-549 SIDT1 KO 1	Cancer cell line	Male
CVCL_B2Q3	Abcam A-549 SIDT1 KO 2	Cancer cell line	Male
CVCL_D7HI	Ubigene HEK293T SIDT1 KO	Transformed cell line	Female

Clinical trials (associated diseases)

66 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT02513940	PHASE4	COMPLETED	Influence of Testosterone Administration on Drug-Induced QT Interval Prolongation and Torsades de Pointes
NCT03834883	PHASE4	COMPLETED	Reducing the Risk of Drug-Induced QT Interval Lengthening in Women
NCT04169100	PHASE4	UNKNOWN	Novel Form of Acquired Long QT Syndrome
NCT04675788	PHASE4	COMPLETED	Novel Approaches for Minimizing Drug-Induced QT Interval Lengthening
NCT01648205	PHASE2	COMPLETED	Long-term Efficacy Study of Sodium Channel Blocker in LQT3 Patients
NCT02412709	PHASE2	UNKNOWN	Long QT Syndrome Screening in Newborns
NCT04581408	PHASE2	COMPLETED	Mutation-specific Therapy for the Long QT Syndrome
NCT00316459	PHASE1	COMPLETED	Study Evaluating the Effects of Multiple Oral Doses of ERB-041 on Cardiac Repolarization in Healthy Subjects
NCT01849003	PHASE1	COMPLETED	Study of the Effect of GS-6615 in Subjects With LQT-3
NCT02365532	PHASE1	COMPLETED	Effect of Oral GS-6615 on Dofetilide-Induced QT Prolongation, Safety, and Tolerability in Healthy Adults
NCT02412098	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Hepatic Function
NCT02441829	PHASE1	COMPLETED	Pharmacokinetics of Eleclazine in Adults With Normal and Impaired Renal Function
NCT05759962	PHASE1	COMPLETED	Phase 1 Study of LQT-1213 in Healthy Adults
NCT05906732	PHASE1/PHASE2	TERMINATED	Study of LQT-1213 on QTc-induced Prolongation in Healthy Adult Subjects (Part1) and on Congenital Long QT in Patients Diagnosed With Type 2 or 3 Long QT Syndrome (Part 2).
NCT00005176	Not specified	COMPLETED	Long QT Syndrome-Population Genetics and Cardiac Studies
NCT00005250	Not specified	COMPLETED	Linkage Study of Long QT Syndrome In An Amish Kindred
NCT00005367	Not specified	COMPLETED	Epidemiology of Long QTand Asian Sudden Death in Sleep
NCT00221832	Not specified	UNKNOWN	Molecular Genetic Screening and Identification of Congenital Arrhythmogenic Diseases
NCT00292032	Not specified	COMPLETED	Registry of Unexplained Cardiac Arrest
NCT00335036	Not specified	TERMINATED	Pediatric Lead Extractability and Survival Evaluation (PLEASE)
NCT00399412	Not specified	COMPLETED	ECG Signal Collection From Long QT Syndrome, Wide QRS Complexes, Heart Failure, and Cardiac Resynchronization Patients
NCT00488254	Not specified	COMPLETED	The Long QT Syndrome in Pregnancy
NCT00588965	Not specified	COMPLETED	Effect of Beta-blocker Therapy on QTc Response in Exercise and Recovery in Normal Subjects
NCT01705925	Not specified	COMPLETED	Multicenter Evaluation of Children and Young Adults With Genotype Positive Long QT Syndrome
NCT01903564	Not specified	COMPLETED	Fetal and Neonatal Magnetophysiology
NCT02082431	Not specified	COMPLETED	Determine the Incidence of Long QT Amongst a Large Cohort of Subjects Diagnosed With Unilateral or Bilateral Sensorineural Hearing Loss.
NCT02413450	Not specified	ENROLLING_BY_INVITATION	Derivation of Human Induced Pluripotent Stem (iPS) Cells to Heritable Cardiac Arrhythmias
NCT02425189	Not specified	COMPLETED	The Canadian National Long QT Syndrome Registry
NCT02439645	Not specified	TERMINATED	A Registry to Determine the Clinical and Genetic Risk Factors for Torsade De Pointes
NCT02439658	Not specified	UNKNOWN	Genetics of QT Prolongation With Antiarrhythmics
NCT02549664	Not specified	COMPLETED	Exercise in Genetic Cardiovascular Conditions
NCT02581241	Not specified	COMPLETED	Abnormal QT-Response to the Sudden Tachycardia Provoked by Standing in Individuals With Drug-induced Long QT Syndrome
NCT02680080	Not specified	COMPLETED	Effect of Grapefruit on QT Interval in Healthy Volunteers and Patients With Congenital Long QT Syndrome
NCT02775513	Not specified	UNKNOWN	Metabolism of Patients With Genetically Caused Cardiac Arrhythmia
NCT02814981	Not specified	UNKNOWN	Hydroxyzine and Risk of Prolongation of QT Interval
NCT02876380	Not specified	COMPLETED	Prospective Identification of Long QT Syndrome in Fetal Life
NCT03182777	Not specified	COMPLETED	Safety of Local Dental Anesthesia in Patients With Cardiac Channelopathies
NCT03544918	Not specified	COMPLETED	Prevalence of Congenital Long QT Syndrome and Acquired QT Prolongation in a Hospital Cohort
NCT03642405	Not specified	UNKNOWN	Drug-induced Repolarization ECG Changes
NCT03678311	Not specified	COMPLETED	Long QT Syndrome and Sleep Apnea